Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00323102 · ClinicalTrials.gov registry record · Phase 4
A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain
A Phase 4 study of Brain Pathology, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- Phase 4
- Development phase
- 114
- Enrollment target
- 1
- Study location
NCT00323102: Completed Phase 4 study of Brain Pathology, sponsored by Bracco Diagnostics.
NCT00323102 is a Phase 4 study of Brain Pathology that has completed, run by Bracco Diagnostics. The registered enrollment target is 114 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00323102, a Phase 4 study of Brain Pathology, has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 114 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims at a direct comparison between Multihance and a validated comparator like Omniscan in a cross-over individual design in patients with brain tumors to confirm the superior overall diagnostic performance of MuliHance for this indication
Conditions Studied
Interventions
- DRUG Multihance
Study Locations (1)
New Jersey
- Bracco Diagnostics, Inc. - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-03 |
| Phase | Phase 4 |
What the finished NCT00323102 record still lists
NCT00323102 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Brain Pathology appearing as the primary indexed condition, and to 1 intervention - of which Multihance is the first listed.
NCT00323102 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00323102 about?
NCT00323102 is a clinical study titled "A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain". This study aims at a direct comparison between Multihance and a validated comparator like Omniscan in a cross-over individual design in patients with brain tumors to confirm the superior overall diagnostic performance of MuliHance for this indication
What is the current status of trial NCT00323102?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 114 participants. The study started on 2006-05. Estimated completion is 2007-03.
What conditions does trial NCT00323102 study?
This clinical trial studies the following conditions: Brain Pathology.
What interventions are being tested in trial NCT00323102?
The interventions under investigation include: Multihance (DRUG).
Who is sponsoring clinical trial NCT00323102?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00323102 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00323102's enrollment target sits among peer trials
114 720th of 2000 higher than 1,278 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04522791 · 114 participants · Phase 2
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
- NCT04875052 · 114 participants · NA
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
- NCT05100342 · 114 participants
Prospective Validation of a Points Score System Predicting 30-day Survival
- NCT05224089 · 114 participants · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia